Sep. 29 at 4:46 PM
$TRVI Boehringer Ingelheim just canceled their IPF Chronic Cough candidate BI 1839100 due to a lack of efficacy in 24 hour reduction in chronic cough frequency. Going to be really hard to beat Haduvio. Boehringer Ingelheim might acquire Trevi to be honest. They have IPF expertise and an interest in that area. They have an FDA approved drug for IPF called Ofev and another pipeline candidate called nerandomilast up for approval for IPF. They both treat lung scarring, not chronic cough frequency though. They need a chronic cough candidate to complete their portfolio in IPF.
